Indian Premier League (IPL): Focus stays on Rohit Sharma fitness

Table-toppers MI are on course to make it to the playoffs but the game is crucial for Rajasthan, who are languishing at seventh place and a loss would mean a step closer to elimination

Rohit Sharma


Skipper Rohit Sharma’s fitness would be a concern for defending champions Mumbai Indians as they aim to continue their dominant run, while a depleted Rajasthan Royals would hope to stay afloat when the two teams clash here on Sunday.

Mumbai roared back to form by crushing Chennai Super Kings by 10 wickets on Friday after their Super Over loss to Kings XI Punjab. Royals, on the other hand, lost to Sunrisers Hyderabad by eight wickets in their last game.

Table-toppers MI are on course to make it to the playoffs but the game is crucial for Rajasthan, who are languishing at seventh place and a loss would mean a step closer to elimination.

Questions remain on whether Rohit, who suffered a hamstring injury and missed the game against CSK, will be available on Sunday. However, Rohit’s absence was hardly felt on Friday as the young Ishan Kishan launched into CSK bowlers with gusto.

So did Quinton de Kock, continuing his sublime run. In the event of Rohit missing out on Sunday as well, the two will open again.

Mumbai’s middle-order has also been among runs — be it Suryakumar Yadav, Hardik Pandya, all-rounder Kieron Pollard or Krunal Pandya. Their bowlers are also wreaking havoc.

Source Article

Read more

NIH Tests Therapies to Help Cut Hospital Stays for COVID-19 Patients | Top News

(Reuters) – The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay.

The NIH said on Friday it has selected three agents for the study – Johnson & Johnson

unit Janssen Research’s Remicade, Bristol Myers Squibb’s

Orencia and Abbvie Inc’s

experimental drug cenicriviroc.

The study will enroll up to 2,100 hospitalized adults with moderate to severe COVID-19 symptoms in the United States and Latin America.

Immune-modulating therapies are medications that alter the way the immune system works. Severe infections are believed to be triggered by an over-reaction of the immune system, known as a “cytokine storm”, and drugs that suppress certain elements of the immune system can play a role in arresting a rapid escalation of symptoms.

This can lead to acute respiratory distress syndrome and multiple organ failure, among other life-threatening complications.

The NIH said its clinical trial – ACTIV-1 Immune Modulators (IM) – will last six months, and the agency will study if the therapeutics can restore balance by modulating that immune response.

All patients will be given Gilead Sciences Inc’s

antiviral drug remdesivir – the current standard of care – and also be randomly assigned to receive a placebo or one of the immune modulators as an add-on treatment, the NIH said in a statement.

Remdesivir was one of the drugs used to treat U.S. President Donald Trump’s coronavirus infection, and has been shown in previous studies to have cut time to recovery, though the European Union is investigating it for possible kidney injury.

(Reporting by Vishwadha Chander in Bengaluru, Editing by Sherry Jacob-Phillips)

Copyright 2020 Thomson Reuters.

Source Article

Read more